Carcinoma, Squamous Cell of the Head and Neck
3
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
7 treatments under study, led by Reolysin
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
33%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (3)
Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Research Network
Common Treatments
- Reolysin2
- Carboplatin2
- Paclitaxel2
- Cetuximab1
- Cisplatin1
Active Sponsors
- Oncolytics Biotech2
- Washington University School of Medicine1
- Celgene Corporation1
Top Investigators
University Hospital, Antwerp, Belgium
The Royal Marsden Hospital, London, UK
University of Alabama at Birmingham, Birmingham, AB, US
Washington University School of Medicine
Cancer Therapy and Research Center, Texas
Related Conditions
- Cancer Of The Head And Neck1
- Cancer Of Head And Neck1
- Neoplasms Head And Neck1
- Head And Neck Cancer1
- Squamous Cell Carcinoma Of The Head And Neck1